Sorrento Therapeutics, Inc.(SRNE.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Sorrento Therapeutics, Inc.
SRNE.US
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease.
1.880 T
SRNE.USMarket value -Rank by Market Cap -/-

Financial Score

19/01/2026 Update
D
BiotechnologyIndustry
Industry Ranking338/398
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE1499.52%A
    • Profit Margin-852.65%E
    • Gross Margin-177.70%E
  • Growth ScoreC
    • Revenue YoY16.89%B
    • Net Profit YoY-4.62%C
    • Total Assets YoY-27.75%E
    • Net Assets YoY-245.81%E
  • Cash ScoreC
    • Cash Flow Margin-11.73%D
    • OCF YoY16.89%B
  • Operating ScoreE
    • Turnover0.12E
  • Debt ScoreE
    • Gearing Ratio143.35%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    How weight-loss drugs are destroying big snacking, erasing billions in sales

    The rise of GLP-1 weight-loss drugs is significantly impacting the food and beverage industry, leading to a projected $48 billion reduction in spending by 2034. Consumers are reducing their snacking frequency and appetite, with major brands like PepsiCo and Mondelez facing declining sales. Traditional marketing strategies are failing as appetite suppression alters consumer behavior, challenging the business models of companies reliant on high-volume sales. Fast-food spending has also dropped among GLP-1 users, indicating a fundamental shift in consumption patterns.

    Invezz·
    US
    PEP
    -0.17%
    US
    MDLZ
    -0.10%
    Invezz·
    US
    PEP
    -0.17%
    US
    MDLZ
    -0.10%

    Profusa launches Lumee Tissue Oxygen healthcare research offerings for immediate revenue generation with products available commercially.

    Commercially available research-use-only offerings now provide companies with the opportunity to quickly generate revenue through product and service sales. These offerings are designed specifically for research purposes and are accessible to businesses seeking to capitalize on this market.

    Unusual Whales·
    US
    PFSA
    +4.06%
    Unusual Whales·
    US
    PFSA
    +4.06%

    Atha Energy secures $25M in LIFE private placement for flow-through shares.

    The number of new COVID-19 cases in the country has increased by 15% in the past week, with over 20,000 new infections reported. Hospitalizations have also risen by 10% during the same period, with a total of 5,000 individuals currently receiving treatment. The vaccination rate continues to climb steadily, with over 40% of the population now fully vaccinated. Authorities are urging the public to adhere to safety protocols to prevent further spread of the virus.

    Unusual Whales·
    Unusual Whales·

    16:06 ET Disrupting Biotech: Jurek Kozyra Unveils DNA Nanorobots That Could Cure the Incurable

    Jurek Kozyra, CEO of Nanovery, discusses on the Disruption Interruption podcast how DNA nanorobots and AI are revolutionizing molecular medicine. These innovations aim to reduce drug development times from 10-15 years to mere hours, potentially curing diseases by targeting mRNA. Kozyra highlights the inefficiencies of traditional medicine and the promise of nanorobots that can detect diseases in blood samples within 2-4 hours, significantly faster than conventional methods. This technology has shown promising results in clinical settings, marking a significant advancement in rapid diagnostics and drug discovery.

    prnewswire·
    US
    CURE
    -2.34%
    US
    NNOX
    +2.61%
    prnewswire·
    US
    CURE
    -2.34%
    US
    NNOX
    +2.61%

    He Yi responded to users' expectations for the CZ role: Diversity needs to be respected, and being down-to-earth does not prevent one from looking up at the stars.

    In response to a user's opinion that "CZ should not only focus on creating memes in the cryptocurrency circle, but should devote himself to future technologies such as AI, human regeneration, and Mars exploration," He Yi responded on social media that diversity itself is an important value of the industry and should be fully respected.

    CoinLive·
    US
    AI
    -3.62%
    CoinLive·
    US
    AI
    -3.62%
    © 2026 Longbridge｜Disclaimer